Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease

A Hye; F Kerr; N Archer; C Foy; M Poppe; R Brown; G Hamilton; J Powell; B Anderton; S Lovestone

doi:10.1016/j.neulet.2004.10.031

Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease

A Hye, F Kerr, N Archer, C Foy, M Poppe, R Brown, G Hamilton, J Powell, B Anderton, S Lovestone

Research output: Contribution to journal › Article › peer-review

111 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is a disorder without a molecular marker in peripheral tissues or a disease modifying treatment. As increasing evidence has suggested a role for glycogen synthase kinase-3 (GSK-3) in the pathogenesis of the condition we measured total GSK-3 protein (alpha and beta isoforms) and GSK-3 activity (serine 9 phosphorylation) in a group of healthy elderly people, in AD and in mild cognitive impairment (MCI). Total GSK-3 protein was increased in both AD and in MCI without a compensatory decrease in activity. These data suggest that GSK-3 assays might be a useful diagnostic marker in a readily available tissue and moreover that GSK-3 activity is increased in the prodromal phase of the disorder suggesting that inhibition of GSK-3 might be a useful therapeutic strategy. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

Original language	English
Pages (from-to)	1 - 4
Number of pages	4
Journal	Neuroscience Letters
Volume	373
Issue number	1
DOIs	https://doi.org/10.1016/j.neulet.2004.10.031
Publication status	Published - 3 Jan 2005

Access to Document

10.1016/j.neulet.2004.10.031

Cite this

@article{6570c3d30de2405890f9bc93061a3863,

title = "Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease",

abstract = "Alzheimer's disease (AD) is a disorder without a molecular marker in peripheral tissues or a disease modifying treatment. As increasing evidence has suggested a role for glycogen synthase kinase-3 (GSK-3) in the pathogenesis of the condition we measured total GSK-3 protein (alpha and beta isoforms) and GSK-3 activity (serine 9 phosphorylation) in a group of healthy elderly people, in AD and in mild cognitive impairment (MCI). Total GSK-3 protein was increased in both AD and in MCI without a compensatory decrease in activity. These data suggest that GSK-3 assays might be a useful diagnostic marker in a readily available tissue and moreover that GSK-3 activity is increased in the prodromal phase of the disorder suggesting that inhibition of GSK-3 might be a useful therapeutic strategy. (C) 2004 Elsevier Ireland Ltd. All rights reserved.",

author = "A Hye and F Kerr and N Archer and C Foy and M Poppe and R Brown and G Hamilton and J Powell and B Anderton and S Lovestone",

year = "2005",

month = jan,

day = "3",

doi = "10.1016/j.neulet.2004.10.031",

language = "English",

volume = "373",

pages = "1 -- 4",

journal = "Neuroscience Letters",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease

AU - Hye, A

AU - Kerr, F

AU - Archer, N

AU - Foy, C

AU - Poppe, M

AU - Brown, R

AU - Hamilton, G

AU - Powell, J

AU - Anderton, B

AU - Lovestone, S

PY - 2005/1/3

Y1 - 2005/1/3

N2 - Alzheimer's disease (AD) is a disorder without a molecular marker in peripheral tissues or a disease modifying treatment. As increasing evidence has suggested a role for glycogen synthase kinase-3 (GSK-3) in the pathogenesis of the condition we measured total GSK-3 protein (alpha and beta isoforms) and GSK-3 activity (serine 9 phosphorylation) in a group of healthy elderly people, in AD and in mild cognitive impairment (MCI). Total GSK-3 protein was increased in both AD and in MCI without a compensatory decrease in activity. These data suggest that GSK-3 assays might be a useful diagnostic marker in a readily available tissue and moreover that GSK-3 activity is increased in the prodromal phase of the disorder suggesting that inhibition of GSK-3 might be a useful therapeutic strategy. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

AB - Alzheimer's disease (AD) is a disorder without a molecular marker in peripheral tissues or a disease modifying treatment. As increasing evidence has suggested a role for glycogen synthase kinase-3 (GSK-3) in the pathogenesis of the condition we measured total GSK-3 protein (alpha and beta isoforms) and GSK-3 activity (serine 9 phosphorylation) in a group of healthy elderly people, in AD and in mild cognitive impairment (MCI). Total GSK-3 protein was increased in both AD and in MCI without a compensatory decrease in activity. These data suggest that GSK-3 assays might be a useful diagnostic marker in a readily available tissue and moreover that GSK-3 activity is increased in the prodromal phase of the disorder suggesting that inhibition of GSK-3 might be a useful therapeutic strategy. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

U2 - 10.1016/j.neulet.2004.10.031

DO - 10.1016/j.neulet.2004.10.031

M3 - Article

VL - 373

SP - 1

EP - 4

JO - Neuroscience Letters

JF - Neuroscience Letters

IS - 1

ER -

Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease

Abstract

Access to Document

Fingerprint

Cite this